A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone
(Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib
refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.